Abscisic Acid Anti-Inflammatory Therapy via PPARγ Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for inflammation induced by lipopolysaccharide (LPS) are limited by significant side effects, and there is a need for effective compounds that can safely attenuate LPS-induced inflammation to treat various human diseases such as septic shock, Parkinson's Disease, Alzheimer's Disease, and cardiovascular disease.

Innovation Solution

Administration of abscisic acid (ABA) or its analogs, which bind to lanthionine synthetase C-like 2 protein and activate peroxisome proliferator-activated receptor γ (PPAR γ), reducing LPS-induced inflammation and modulating immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing anti-inflammatory treatments are used to treat LPS-induced inflammation, then inflammation is reduced, but significant side effects occur including fluid retention, weight gain and hepatotoxicity

Engineering Contradiction:

Improveanti-inflammatory efficacyVSAvoidside effects (fluid retention, weight gain, hepatotoxicity)

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs abscisic acid (ABA), a natural plant hormone, as a temporary, biodegradable anti-inflammatory agent that acts locally at the site of inflammation without accumulating in the body. ABA is metabolized and eliminated naturally, avoiding the persistent toxic effects of synthetic drugs like TZDs. This approach provides effective inflammation control while eliminating long-term side effects through the use of a natural, short-acting compound.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent introduces abscisic acid as an intermediary substance that mediates anti-inflammatory effects through a novel mechanism involving PPARγ activation and cAMP/PKA pathway modulation. ABA acts as a bridge between natural plant compounds and human inflammatory pathways, providing therapeutic effects without directly engaging the harmful mechanisms that cause TZD side effects. This intermediary approach allows selective anti-inflammatory action while sparing metabolic and hepatic systems from damage.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If TZDs are used to activate PPAR γ for anti-inflammatory effects, then inflammation is suppressed, but significant side effects including fluid retention, weight gain and hepatotoxicity occur

Engineering Contradiction:

Improveanti-inflammatory efficacyVSAvoidside effects (fluid retention, weight gain, hepatotoxicity)

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent replaces persistent synthetic TZD molecules with abscisic acid, a natural plant hormone that is rapidly metabolized and eliminated. ABA provides transient PPARγ activation sufficient for anti-inflammatory effects but does not accumulate in adipose tissue or liver, thereby avoiding the metabolic side effects and hepatotoxicity associated with long-term TZD use.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent uses abscisic acid as a natural intermediary that activates PPARγ through a different molecular mechanism than TZDs. ABA binds to and activates PPARγ receptors in inflammatory cells, triggering anti-inflammatory gene expression without engaging the same metabolic pathways that lead to TZD-induced fluid retention, weight gain, and liver toxicity. This intermediary approach achieves the desired anti-inflammatory effect through a safer biological pathway.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If current anti-inflammatory therapies are administered, then LPS-induced inflammation is treated, but the treatments are limited by significant side effects

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects limiting therapy adoption

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent fundamentally changes the chemical and biological parameters of anti-inflammatory therapy by switching from synthetic TZD molecules to the natural plant hormone abscisic acid. This parameter change includes differences in molecular structure, metabolism, and mechanism of action. ABA's natural origin and rapid clearance kinetics provide effective inflammation control while eliminating the side effect profile that limits current therapy adoption, particularly in chronic inflammatory conditions.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

ABA treatment effectively decreases lung inflammation, ameliorates respiratory disease activity, and increases survival rates following influenza virus infection, suggesting its potential in treating LPS-induced conditions without the side effects associated with existing therapies.

Implementation Method 1

ABA and its analogs can regulate immune responses and inflammation involving binding to lanthionine synthetase C-like 2 protein and activation of peroxisome proliferator-activated receptor γ (PPAR γ)

Methodology Applied

Scientific EffectReceptor activation:

Data Source

PatentUS8993624B2Method of preventing and treating inflammatory diseases and disorders with abscisic acid

Publication Date: 2015.03.31 VIRGINIA TECH INTELLECTUAL PROPERTIES INC

AI summary

The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.